NDATOPICALSOLUTIONPriority Review
Approved
Aug 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
Priority Review
ROGAINE (FOR MEN) (minoxidil) by Design Pharmaceuticals is clinical pharmacology 1. First approved in 1988.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Rogaine (minoxidil) is a topical solution originally developed as an oral vasodilator for severe hypertension, now repurposed for androgenetic alopecia (male pattern baldness). It works by enhancing microcirculatory blood flow to hair follicles and extending the anagen (growth) phase of the hair cycle. The drug is applied directly to the scalp to stimulate hair regrowth in men experiencing hair loss.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%); teams may be consolidating or transitioning to cost-optimization and generic defense strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY 1. General Pharmacologic Properties Minoxidil is an orally effective direct acting peripheral vasodilator that reduces elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. Microcirculatory blood flow in animals is enhanced or maintained…
Worked on ROGAINE (FOR MEN) at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.